747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors.
Saved in:
| Title: | 747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. |
|---|---|
| Authors: | Falchook, G.S.1 (AUTHOR), Fu, S.2 (AUTHOR), Lemech, C.3 (AUTHOR), Mckean, M.A.4 (AUTHOR), Azad, A.A.5 (AUTHOR), Gan, H.K.6 (AUTHOR), Sommerhalder, D.7 (AUTHOR), Wang, J.S.8 (AUTHOR), Tan, T.J.Y.9 (AUTHOR), Chee, C.E.10 (AUTHOR), Barve, M.11 (AUTHOR), Moser, J.12 (AUTHOR), Mooney, J.13 (AUTHOR), Acuff, N.13 (AUTHOR), Wang, R.14 (AUTHOR), Marina, N.14 (AUTHOR), Abbadessa, G.14 (AUTHOR), Streit, M.14 (AUTHOR), Ramusovic, S.15 (AUTHOR), Meniawy, T.16 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS885-S886. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 159077665 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Falchook%2C+G%2ES%2E%22">Falchook, G.S.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fu%2C+S%2E%22">Fu, S.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lemech%2C+C%2E%22">Lemech, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mckean%2C+M%2EA%2E%22">Mckean, M.A.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Azad%2C+A%2EA%2E%22">Azad, A.A.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gan%2C+H%2EK%2E%22">Gan, H.K.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sommerhalder%2C+D%2E%22">Sommerhalder, D.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+J%2ES%2E%22">Wang, J.S.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tan%2C+T%2EJ%2EY%2E%22">Tan, T.J.Y.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chee%2C+C%2EE%2E%22">Chee, C.E.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barve%2C+M%2E%22">Barve, M.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moser%2C+J%2E%22">Moser, J.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mooney%2C+J%2E%22">Mooney, J.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Acuff%2C+N%2E%22">Acuff, N.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+R%2E%22">Wang, R.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marina%2C+N%2E%22">Marina, N.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Abbadessa%2C+G%2E%22">Abbadessa, G.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Streit%2C+M%2E%22">Streit, M.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ramusovic%2C+S%2E%22">Ramusovic, S.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meniawy%2C+T%2E%22">Meniawy, T.</searchLink><relatesTo>16</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2022 Supplement 7, Vol. 33, pS885-S886. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=159077665 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2022.07.873 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S885 Titles: – TitleFull: 747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Falchook, G.S. – PersonEntity: Name: NameFull: Fu, S. – PersonEntity: Name: NameFull: Lemech, C. – PersonEntity: Name: NameFull: Mckean, M.A. – PersonEntity: Name: NameFull: Azad, A.A. – PersonEntity: Name: NameFull: Gan, H.K. – PersonEntity: Name: NameFull: Sommerhalder, D. – PersonEntity: Name: NameFull: Wang, J.S. – PersonEntity: Name: NameFull: Tan, T.J.Y. – PersonEntity: Name: NameFull: Chee, C.E. – PersonEntity: Name: NameFull: Barve, M. – PersonEntity: Name: NameFull: Moser, J. – PersonEntity: Name: NameFull: Mooney, J. – PersonEntity: Name: NameFull: Acuff, N. – PersonEntity: Name: NameFull: Wang, R. – PersonEntity: Name: NameFull: Marina, N. – PersonEntity: Name: NameFull: Abbadessa, G. – PersonEntity: Name: NameFull: Streit, M. – PersonEntity: Name: NameFull: Ramusovic, S. – PersonEntity: Name: NameFull: Meniawy, T. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2022 Supplement 7 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
